Blog
OSTEOARTHRITIS AND VISCOSUPPLEMENTATION – Advertorial – Chemistry today
Osteoarthritis, the most common cause of musculoskeletal disability. Let’s find out more with the IBSA NAHYCO® HYBRID TECHNOLOGY .
Read the Whole InterviewRelated Articles
+
12.10.2023
CPHI October 24-26 Barcelona: IBSA presents cutting-edge technologies to drive pharmaceutical innovation.
As a global pharmaceutical company, IBSA is driven by a distinct vision of care, which starts at the Swiss headquarters and extends globally through continued growth in Europe, Asia, and North America. IBSA’s technologies are aimed at creating more advanced treatment systems to provide healthcare professionals with innovative, effective and reliable therapeutic solutions that improve patients’ quality of life. The product portfolioRead more